Compare Globus Medical Inc. Class A Common Stock (GMED) vs HDFC Bank Limited Common Stock (HDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs HDFC Bank Limited Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while HDFC Bank Limited Common Stock trades at $23.14 (market cap $114.94B). The key difference: HDFC Bank Limited Common Stock is far larger — about 11.2× Globus Medical Inc. Class A Common Stock's market cap, and HDFC Bank Limited Common Stock pays a 1.8% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and HDFC Bank Limited Common Stock for 6 Days on average.
| GMED | HDB | |
|---|---|---|
Market Cap | $10.25B | $114.94B |
Volume | 1,108,124 | 6,516,078 |
Sector | Health | Financials |
52-Week High | $96.82 | $37.18 |
52-Week Low | $58.33 | $21.84 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $14.23T |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
HDFC Bank (HDB) trades at $22.76, up 0.8% with neutral technical indicators. The bank maintains strong profitability with 28.24% net income margin and consistent earnings beats. However, significant legal headwinds emerge as multiple class action lawsuits approach deadlines in October 2026, creating investor uncertainty despite solid fundamentals.
While HDB demonstrates financial strength with improving debt-to-asset ratios and positive cash flow projections for 2026, the pending securities litigation represents a material risk. Analyst consensus leans cautious with 67% hold ratings, suggesting investors await legal clarity before more bullish positioning despite attractive valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About HDFC Bank Limited Common Stock
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →
